Cambridge, Mass. — InduPro, Inc., a biotechnology company developing novel therapeutics by defining membrane protein spatial relationships, has entered into a strategic equity investment and research collaboration with Sanofi. The agreement grants Sanofi the right of first negotiation for InduPro’s bispecific PD-1 agonist program, a preclinical candidate being developed for autoimmune and inflammatory diseases.
“We are thrilled to collaborate with Sanofi to advance toward the clinic our bispecific PD-1 agonist program. Sanofi’s know-how and global leadership position in autoimmune and inflammatory diseases make them the ideal partner to bring this exciting first-in-class molecule forward,” said Prakash Raman, Ph.D., Chief Executive Officer of InduPro. “In addition, we welcome Sanofi’s strategic equity investment into InduPro, which further reinforces the strength of our collaboration.”
Under the terms of the agreement, the companies will jointly conduct preclinical and IND-enabling research activities. Sanofi will provide funding for this work and will also make an undisclosed equity investment in InduPro.
InduPro’s platform focuses on therapeutically targeting cell surface proteins by leveraging inherent or induced protein proximity. Using its proprietary high-resolution proximity labeling technology to map protein neighborhoods with precision, the company identifies novel co-target combinations that are highly selective for disease biology. Targeting these pairs through induced proximity offers a new mechanism for modulating cellular signaling pathways that are central to disease regulation. This discovery engine supports the development of potential first-in-class and best-in-class therapeutic candidates across multiple modalities and indications.
